Clarify Medical, developer of the Clarify Medical® Home Light Therapy System, a software-controlled home phototherapy system for the treatment of psoriasis, vitiligo, eczema, and other skin conditions, today announced that the United States Patent and Trademark Office has issued US patent 9,9913,993, entitled “Systems And Methods For Phototherapy.” The patent covers technology which enables patients to treat at home with controlled dosing protocols prescribed by physicians. This news follows last month’s patent issuance for Clarify Medical’s lighting engine technology.

Clarify Medical’s lightweight, hand-held phototherapy system has significant advantages compared to conventional phototherapy systems. Treatment schedules are managed by the Clarify smartphone app and can be monitored remotely, which helps to improve treatment adherence. Dosing is optimized for each body location and is automatically controlled, which simplifies the administration process for patients. Treatment records and patient-reported outcome measures are collected and compiled in a web-based application, allowing patients and physicians to monitor progress throughout the course of therapy.

Rex Bright, Interim President and CEO of Clarify Medical commented, “One of the biggest problems with conventional home phototherapy is non-adherence.” He adds, “We believe that the features covered by this patent – phototherapy treatment scheduling and reminders in the app, and ongoing monitoring by the physician – will help solve that problem.”

The Clarify System received FDA clearance in May 2017 with indications for the treatment of vitiligo, psoriasis, eczema, seborrheic dermatitis and leucoderma on all skin types (I-VI).